Trial Profile

An Open-Label, Phase 1/1b Study of ORIC-944 As a Single Agent or in Combination with an Androgen Receptor Pathway Inhibitor in Patients with Metastatic Prostate Cancer

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 20 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Apalutamide (Primary) ; Darolutamide (Primary) ; Rinzimetostat (Primary)
Indications Neuroendocrine carcinoma; Prostate cancer
Focus Adverse reactions; First in man; Pharmacokinetics
Sponsors ORIC Pharmaceuticals

Most Recent Events

09 Jul 2026 Planned number of patients changed from 250 to 275.
09 Jul 2026 Planned End Date changed from 1 Sep 2026 to 1 Apr 2028.
09 Jul 2026 Planned primary completion date changed from 1 Dec 2025 to 1 Jun 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com